FDA rejects two HIV drugs from Gilead Sciences

Gilead Sciences Inc. says that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company's manufacturing facilities.

The FDA informed the company in a letter that it cannot approve its HIV pills elvitegravir and cobicistat for use in managing the virus that causes AIDS.

The agency noted that in recent inspections regulators have found problems with documentations and quality testing at Gilead Sciences' facilities.

The company said in a release it is working to address the issues raised by the agency.

Explore further

US delays decision on first drug to prevent HIV

© 2013 The Associated Press. All rights reserved.

Citation: FDA rejects two HIV drugs from Gilead Sciences (2013, April 29) retrieved 26 May 2020 from https://medicalxpress.com/news/2013-04-fda-hiv-drugs-gilead-sciences.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments